These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31566097)

  • 1. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
    Solidoro P; Patrucco F; Libertucci D; Verri G; Sidoti F; Curtoni A; Boffini M; Simonato E; Rinaldi M; Cavallo R; Costa C
    Ther Adv Respir Dis; 2019; 13():1753466619878555. PubMed ID: 31566097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant.
    Kervan U; Kucuker SA; Kocabeyoglu SS; Unal EU; Ozatik MA; Sert DE; Kavasoglu K; Tezer AY; Pac M
    Exp Clin Transplant; 2016 Oct; 14(5):551-554. PubMed ID: 26976362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
    Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
    Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
    Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
    Rea F; Potena L; Yonan N; Wagner F; Calabrese F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S19-26. PubMed ID: 26900991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice.
    Solidoro P; Patrucco F; Boffini M; Rinaldi M; Airoldi C; Costa C; Cavallo R; Albera C
    Ther Adv Respir Dis; 2020; 14():1753466620981851. PubMed ID: 33356914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
    Natori Y; Humar A; Husain S; Rotstein C; Renner E; Singer L; Kim SJ; Kumar D
    Transplantation; 2017 Jun; 101(6):1449-1454. PubMed ID: 27467535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA; Brennan DC; Yusen RD; Olsen MA
    Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.
    Carbone J
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S11-8. PubMed ID: 26900990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
    Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.
    Kabbani D; Hirji A; Hernandez C; Malhi H; Mabilangan C; Chandrarathne S; Halloran K; Weinkauf J; Kapasi A; Lien D; Preiksaitis J; Cervera C
    Transpl Infect Dis; 2019 Aug; 21(4):e13094. PubMed ID: 30985048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus viremia in lung transplantation during and after prophylaxis.
    Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P
    Transpl Infect Dis; 2019 Jun; 21(3):e13069. PubMed ID: 30884067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation.
    Solidoro P; Delsedime L; Bergallo M; Libertucci D; Ruffini E; Costa C; Rinaldi M; Amoroso A; Baldi S
    Transplant Proc; 2009 May; 41(4):1347-8. PubMed ID: 19460556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.